Molecular structure of enalaprilatMolecular structure of enalaprilat
Find information on thousands of medical conditions and prescription drugs.

Enalapril

Enalapril is an angiotensin converting enzyme (ACE) inhibitor used in the treatment of hypertension and some types of chronic heart failure. Enalapril was the first member of the group of ACE inhibitors known as the dicarboxylate-containing ACE inhibitors. It is marketed by Merck & Co. (Merck, Sharp & Dohme) under the trade names, RenitecĀ® and VasotecĀ®. more...

Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Development

Enalapril was developed by researchers at Merck & Co. as part of their efforts to develop novel treatments for hypertension by modulating the renin-angiotensin-aldosterone (RAS) system.

The success of Squibb in developing the first inhibitor, captopril, provided a major impetus for Merck's research laboratories to develop a competing product. Captopril was not without its problems, however, as it was believed (and shown to be true) that the sulfhydryl-moeity of captoril was responsible for such adverse effects as metallic taste.

Enalaprilat

Enalaprilat, the first dicarboxylate-containing ACE inhibitor, was developed partly to overcome these limitations of captopril. The sulfhydryl-moeity was replaced by a carboxylate-moeity, but additional modifications were required in its structure-based design to achieve a similar potency to captopril.

Enalaprilat itself, however, was not without its problems. The consequence of the structural modifications was that it proved to be have unfavourable ionisation characteristics to allow sufficient potency for oral administration (in tablets). Thus enalaprilat was only suitable for intravenous administration. This was overcome by the researchers at Merck by the esterification of enalaprilat with ethanol to produce enalapril. As a prodrug, enalapril is metabolised in vivo to the active form enalaprilat by various esterases.

A prototype for others

Most importantly, perhaps, the QSAR-based modifications in structure serendipitously led to an improved understanding of the structure of ACE which aided in the development of subsequent carboxylate-containing ACE inhibitors.

Read more at Wikipedia.org


[List your site here Free!]


Enalapril Dosing in Heart Failure
From Family Pratice News, 1/15/01

High doses of enalapril do not reduce mortality or improve clinical status in congestive heart failure, as some small-scale studies have suggested, said Dr. John N. Nanas of the University of Athens (Greece) and his associates.

In their randomized prospective trial, 122 patients were assigned to receive the customary dosage of enalapril (the maximal tolerated dosage, up to 10 mg twice daily); 126 patients were assigned to receive higher dosages (the maximal tolerated dosage, up to 30 mg twice daily). Patients received concomitant treatment as needed with digoxin, nitrates, and diuretics.

Mortality was about 18% in both groups after 1 year. Both dosages improved patients' clinical condition, left ventricular ejection fractions, and functional status to similar degrees over the first 3 months of therapy, without further improvement over the next 9 months of follow-up.

Although higher doses of enalapril do not improve survival overall, it is possible that certain subgroups of patients might benefit from higher doses, they noted (J. Am. Coll. Cardiol. 36[7]:2090-95, 2000).

COPYRIGHT 2001 International Medical News Group
COPYRIGHT 2001 Gale Group

Return to Enalapril
Home Contact Resources Exchange Links ebay